Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 11Terminated 3Active not recruiting 3Unknown 2Recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Gemcitabine 13Specimen Handling 12Radiotherapy 12Androgen Antagonists 12Magnetic Resonance Spectroscopy 10Nivolumab 9pembrolizumab 8darolutamide 7Drug Therapy 7toripalimab 6Radiosurgery 6Docetaxel 6Cystectomy 6enzalutamide 5apalutamide 5Mitomycin 5Cisplatin 5Abiraterone Acetate 5disitamab vedotin 4cabozantinib 4abiraterone 4Pluvicto 4Ipilimumab 4Cyclophosphamide 4Biopsy 4Axitinib 4tislelizumab 3lenvatinib 3fludarabine 3cemiplimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × fluciclovine F-18 × Genitourinary × Clear all
NCT07569926 2026-06-02

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Blue Earth Diagnostics

Phase 4 Not yet recruiting
142 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡